Zhejiang Huahai Stock Hits Day High with 4.44% Surge

Zhejiang Huahai Pharmaceutical Co., Ltd. has experienced a notable increase of 4.44% on March 6, 2026, reaching an intraday high of CNY 16.07. This performance stands in contrast to the China Shanghai Composite, which saw a modest gain of 0.38% on the same day. Despite this day's positive movement, the company's longer-term performance metrics reveal a more complex picture. Over the past year, Zhejiang Huahai has generated a return of just 1.52%, significantly lagging behind the broader market's return of 22.49%. The company's market capitalization is currently CNY 22,852 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology sector. Financially, Zhejiang Huahai faces challenges, including a debt-to-equity ratio of 0.70 and a return on equity of 4.24%. The company has reported a decline in net sales of 11.88% and a negative operating profit growth rate of 13.17% over the last five years. These factors contribute to a complex financial landscape, even as the stock shows short-term gains.